Meeting
2023 ASCO Annual Meeting
A phase 2, open-label, multicenter study investigating efficacy and safety of RP3 oncolytic immunotherapy combined with other therapies in patients with locoregionally advanced or recurrent squamous cell carcinoma of the head and neck.
Authors
Kevin Joseph Harrington
The Institute of Cancer Research, The Royal Marsden Hospital, London, United Kingdom
Kevin Joseph Harrington , Ezra Cohen , Dan Paul Zandberg , Terry A. Day , Jessica Lyn Geiger , Marc Oliva , Ricard Mesia , David Michael Cohan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT05743270
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS6106)
DOI
10.1200/JCO.2023.41.16_suppl.TPS6106
Abstract #
TPS6106
Poster Bd #
95b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Nanoparticle albumin-bound (nab) paclitaxel in combination with nivolumab as treatment of recurrent or metastatic head and neck squamous-cell carcinoma (RM-HNSCC) that progressed on a PD-1 inhibitor: A single-arm, phase 2 trial.
First Author: Jared Cohen
Poster
2016 ASCO Annual Meeting
Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).
First Author: Makoto Tahara
First Author: Akhil Kapoor
